july sunovion pharmaceuticals inc became part sumitomo pharma america sciencebased technologydriven biopharmaceutical company focused delivering therapeutic scientific breakthroughs areas critical patient need spanning psychiatry neurology oncology urology womens health rare disease cell gene therapies sunovion founded sepracor inc timothy j barberich steve matson bob bratzler sepracor completed initial public offering trading nasdaq ticker sepr october sepracor inc acquired became standalone subsidiary sumitomo pharma japan known sumitomo dainippon pharma april sumitomo pharma announced combination us subsidiaries including sunovion form sumitomo pharma america sepracor completed initial public offering market cap companys initial focus separation purification isomers active metabolites strategy present larger pharmaceuticals patented purified active ingredients expiring products marion merrell dow part sanofi partnered sepracor develop purified version antihistamine seldane latter required carry warning potentially fatal cardiac arrhythmia purified compound would later marketed allegra sepracor would profit significantly launch result lessthan favorable partnership terms sepracors subsequent products focused treatment central nervous system respiratory disorders direction gunnar aberg john mccullough primary source revenue late early approximately million annually xopenex franchise drugs insomnia drug lunesta eszopiclone approved us food drug administration fda december launched april fda approved sepracors drug brovana treat chronic obstructive pulmonary disease bial agreed company produce market antiepileptic drug aptiom sepracors facilities supervised aptiom subsequently received fda approval treat partial onset seizures latuda atypical antipsychotic drug received fda approval treatment schizophrenia received secondary approval treatment depressive episodes associated bipolar disorder sepracor acquired thensumitomo dainippon pharma sepracor would become indirect wholly owned subsidiary dainippon sumitomo pharma renamed sunovion april sunovion pharmaceuticals indirect wholly owned subsidiary sumitomo pharma co ltd announced combine sumitomo pharma affiliate companies sumitomo pharma america holdings inc sumitovant biopharma ltd myovant sciences inc urovant sciences inc enzyvant therapeutics inc sumitomo pharma oncology inc form sumitomo pharma america inc smpa effective july following illustration companys major mergers acquisitions historical predecessors httpsenwikipediaorgwikisunovion